JG
ELVN icon

Jefferies Group’s Enliven Therapeutics ELVN Stock Holding History

Jefferies Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$238K Buy
+26,075
New +$154K ﹤0.01% 1314

Other funds holding ELVN

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Jefferies Group's ELVN Position: Q3 2022 in Review

Jefferies Group opened a new position in Enliven Therapeutics (ELVN) in Q3 2022: 26,075 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #1314 among its holdings.

31 funds tracked by Wall St. Rank hold ELVN as of Q3 2022.

  • Jefferies Group held 26,075 shares of Enliven Therapeutics worth $238K as of Q3 2022.
  • Enliven Therapeutics was a new Jefferies Group position in Q3 2022.
  • Enliven Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1314 holding.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.